Evaluate the safety and tolerability of hyzaar(R) (losartan 50 mg/ hydrochlorothiazide 12.5 mg) in the treatment of hypertension.
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs Losartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Feb 2007 Status changed from recruiting.
- 05 Dec 2006 New trial record.